Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics

Emergent Biosolutions, Inc. (EBS): $36.67

1.34 (+3.79%)

POWR Rating

Component Grades













Add EBS to Watchlist
Sign Up

Industry: Biotech



in industry


  • EBS scores best on the Value dimension, with a Value rank ahead of 99.48% of US stocks.
  • The strongest trend for EBS is in Momentum, which has been heading down over the past 179 days.
  • EBS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

EBS Stock Summary

  • EBS's current price/earnings ratio is 9.61, which is higher than only 24.06% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for EBS is currently 6.91, higher than 26.16% of US stocks with positive operating cash flow.
  • Emergent BioSolutions Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 5.68%, greater than the shareholder yield of 75.08% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Emergent BioSolutions Inc are CSGS, MDRX, RNWK, SPOK, and ONTO.
  • Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.

EBS Valuation Summary

  • In comparison to the median Healthcare stock, EBS's price/sales ratio is 82.38% lower, now standing at 2.
  • Over the past 180 months, EBS's price/sales ratio has gone down 0.9.
  • EBS's EV/EBIT ratio has moved down 34.7 over the prior 180 months.

Below are key valuation metrics over time for EBS.

Stock Date P/S P/B P/E EV/EBIT
EBS 2021-08-31 2 2.2 11.3 8.7
EBS 2021-08-30 2 2.2 11.5 8.8
EBS 2021-08-27 2 2.2 11.5 8.9
EBS 2021-08-26 2 2.2 11.3 8.7
EBS 2021-08-25 2 2.2 11.5 8.9
EBS 2021-08-24 2 2.2 11.3 8.7

EBS Growth Metrics

    The 3 year price growth rate now stands at 24.49%.
  • Its 4 year revenue growth rate is now at 94.3%.
  • Its 5 year price growth rate is now at 105.48%.
Over the past 34 months, EBS's revenue has gone up $937,514,000.

The table below shows EBS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,792.7 321.1 230.9
2021-09-30 1,652.5 237.2 227
2021-06-30 1,708.7 325.7 299.2
2021-03-31 1,705.9 483.3 387.3
2020-12-31 1,555.4 536 305.1
2020-09-30 1,332.7 413 166.6

EBS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EBS has a Quality Grade of C, ranking ahead of 50.38% of graded US stocks.
  • EBS's asset turnover comes in at 0.604 -- ranking 57th of 681 Pharmaceutical Products stocks.
  • ARWR, IBIO, and MCRB are the stocks whose asset turnover ratios are most correlated with EBS.

The table below shows EBS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.604 0.623 0.227
2021-03-31 0.628 0.680 0.298
2020-12-31 0.607 0.663 0.247
2020-09-30 0.550 0.633 0.146
2020-06-30 0.536 0.645 0.152
2020-03-31 0.478 0.622 0.076

EBS Price Target

For more insight on analysts targets of EBS, see our EBS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.71 Average Broker Recommendation 1.69 (Moderate Buy)

EBS Stock Price Chart Interactive Chart >

Price chart for EBS

EBS Price/Volume Stats

Current price $36.67 52-week high $68.03
Prev. close $35.33 52-week low $27.61
Day low $36.48 Volume 4,160,800
Day high $40.45 Avg. volume 674,220
50-day MA $37.72 Dividend yield N/A
200-day MA $45.93 Market Cap 1.84B

Emergent Biosolutions, Inc. (EBS) Company Bio

Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.

EBS Latest News Stream

Event/Time News Detail
Loading, please wait...

EBS Latest Social Stream

Loading social stream, please wait...

View Full EBS Social Stream

Latest EBS News From Around the Web

Below are the latest news stories about Emergent BioSolutions Inc that investors may wish to consider to help them evaluate EBS as an investment opportunity.

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Bob Burrows - IR Officer Bob Kramer - President and CEO Rich Lindahl - CFO Adam Havey - Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Jessica Fye - JPMorgan...

SA Transcripts on Seeking Alpha | February 25, 2022

Emergent BioSolutions Stock Fell Today -- Is It a Buy?

Emergent BioSolutions (NYSE: EBS) ended the week on a down note. Shares of the company closed 6.2% lower on Friday after it provided its fourth-quarter update following the market close on Thursday. There certainly were some positive takeaways for investors in Emergent's Q4 results.

Yahoo | February 25, 2022

Emergent BioSolutions to begin 'facility improvements' in Baltimore as J&J evaluates Covid vaccine demand

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) plans to begin “facility improvements” at its Baltimore manufacturing plant as Johnson & Johnson (NYSE: JNJ) assesses demand for its Covid-19 vaccine, which the local company has been producing at that site. The company is using the window “to being our normally scheduled maintenance period for our Bayview facility earlier than anticipated, and also to extend it in order to make improvements and modifications,” Kramer said on the call. “These enhancements will enable us to meet the needs of J&J while planning for Bayview's future return to nonpandemic work as part of our [contract development and manufacturing organization] network, a key step in enhancing and advancing the growth of our CDMO business,” he said.

Yahoo | February 25, 2022

Why Emergent BioSciences Stock Is Slipping Today

Shares of Emergent BioSolutions (NYSE: EBS) were slipping 3.8% as of 11:38 a.m. ET on Friday and fell as much as 7.7% earlier in the day. Emergent reported fourth-quarter revenue of $723 million, up 24% year over year. Emergent cut its full-year 2022 outlook.

Yahoo | February 25, 2022

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

Yahoo | February 25, 2022

Read More 'EBS' Stories Here

EBS Price Returns

1-mo -1.58%
3-mo -13.17%
6-mo -15.06%
1-year -37.32%
3-year -15.25%
5-year 21.14%
YTD -15.64%
2021 -51.48%
2020 66.08%
2019 -8.99%
2018 27.57%
2017 41.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7221 seconds.